Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

NEW: Price Reaction to Earnings Reports

View detailed tables showing price action before and after earnings announcements, ranging from intraday to one week out. Track how the market has reacted to past earnings to identify patterns and predict future behavior. Click here to open.

AXSM

Axsome Therapeutics Inc

Dec 10 • 04:00PM ET

98.82

Dollar change -0.94
Percentage change -0.95	%

Healthcare • Biotechnology • USA • NASD

Peers: BIIB ACAD VRTX ALKS NBIX BHVN SAGE PRTA AVDL RARE

| Held by: VTI IWM VB VXF VBK IWO IBB SCHA VTWO IHE

Scroll to Statements

Index	RUT	P/E	-	EPS (ttm)	-6.54	Insider Own	18.44%	Shs Outstand	48.44M	Perf Week	-1.67%
Market Cap	4.79B	Forward P/E	-	EPS next Y	-1.52	Insider Trans	-0.65%	Shs Float	39.53M	Perf Month	9.71%
Income	-310.95M	PEG	-	EPS next Q	-0.96	Inst Own	79.07%	Short Float	17.90%	Perf Quarter	8.55%
Sales	338.46M	P/S	14.15	EPS this Y	-3.05%	Inst Trans	-5.57%	Short Ratio	15.28	Perf Half Y	39.04%
Book/sh	1.92	P/B	51.52	EPS next Y	71.95%	ROA	-53.51%	Short Interest	7.08M	Perf Year	40.80%
Cash/sh	6.75	P/C	14.63	EPS next 5Y	-	ROE	-171.61%	52W Range	64.11 - 105.00	Perf YTD	24.16%
Dividend Est.	-	P/FCF	-	EPS past 5Y	-35.53%	ROI	-110.15%	52W High	-5.89%	Beta	1.01
Dividend TTM	-	Quick Ratio	2.37	Sales past 5Y	88.16%	Gross Margin	88.88%	52W Low	54.13%	ATR (14)	3.44
Dividend Ex-Date	-	Current Ratio	2.44	EPS Y/Y TTM	-44.44%	Oper. Margin	-72.64%	RSI (14)	56.51	Volatility	2.99% 4.08%
Employees	545	Debt/Eq	2.07	Sales Y/Y TTM	51.47%	Profit Margin	-91.87%	Recom	1.06	Target Price	131.44
Option/Short	Yes / Yes	LT Debt/Eq	2.04	EPS Q/Q	-1.66%	Payout	-	Rel Volume	0.79	Prev Close	99.76
Sales Surprise	5.45%	EPS Surprise	3.14%	Sales Q/Q	81.27%	Earnings	Nov 12 BMO	Avg Volume	463.04K	Price	98.82
SMA20	1.05%	SMA50	6.69%	SMA200	18.74%	Trades		Volume	390,535	Change	-0.95%

Date	Action	Analyst	Rating Change	Price Target Change
Sep-03-24	Initiated	Wells Fargo	Overweight	$140
Aug-06-24	Upgrade	BofA Securities	Neutral → Buy	$95 → $106
Jul-22-24	Initiated	Needham	Buy	$130
Apr-29-24	Upgrade	Morgan Stanley	Equal-Weight → Overweight	$90 → $115
Mar-19-24	Initiated	Robert W. Baird	Outperform	$108
Feb-06-24	Initiated	UBS	Buy	$111
Jan-25-24	Initiated	RBC Capital Mkts	Outperform	$126
Dec-13-23	Initiated	Citigroup	Buy	$125
Aug-08-23	Upgrade	BofA Securities	Underperform → Neutral	$59 → $81
Jan-05-23	Initiated	Piper Sandler	Neutral	$75
Nov-01-22	Initiated	Loop Capital	Buy	$95
Sep-07-22	Resumed	Mizuho	Buy	$49 → $76
Aug-10-21	Downgrade	Morgan Stanley	Overweight → Equal-Weight	$105 → $34
Jun-10-21	Initiated	Berenberg	Buy	$112
Jan-08-21	Initiated	Jefferies	Buy	$129
Dec-16-20	Initiated	Mizuho	Buy	$120
Sep-29-20	Initiated	BofA Securities	Underperform	$66
Sep-10-20	Initiated	Morgan Stanley	Overweight	$102
Apr-28-20	Reiterated	H.C. Wainwright	Buy	$200 → $210
Apr-14-20	Initiated	Cowen	Outperform	$95

Show Previous Ratings

Nov-27-24 01:23PM	Axsome Therapeutics' AXS-12 Data For Sleeping Disorder Boosts Confidence In Approval And Market Potential, Analyst Says (Benzinga)
Nov-26-24 07:00AM	Axsome Therapeutics Announces AXS-12 Achieves Primary Endpoint in ENCORE Long-Term Phase 3 Trial in Narcolepsy (GlobeNewswire)
Nov-13-24 03:27AM	Q3 2024 Axsome Therapeutics Inc Earnings Call (Thomson Reuters StreetEvents)
Nov-12-24 03:15PM	Axsome Therapeutics (AXSM) Q3 2024 Earnings Call Transcript (Motley Fool) +9.35%
12:42PM	Axsome Hits 52-Week High After Surging Nearly 5%--FDA Milestones Could Fuel Even Bigger Gains (GuruFocus.com)
07:00AM	Loading…
07:00AM	Axsome Therapeutics Reports Third Quarter 2024 Financial Results and Provides Business Update (GlobeNewswire)
Nov-08-24 07:00AM	Axsome Therapeutics Presents Data from Its Leading Neuroscience Pipeline at NEI Congress 2024 (GlobeNewswire)
Nov-05-24 10:00AM	Analysts Estimate Axsome Therapeutics (AXSM) to Report a Decline in Earnings: What to Look Out for (Zacks)
Oct-29-24 07:00AM	Axsome Therapeutics Presents Data from Multiple Programs Spanning Its Innovative Neuroscience Portfolio at Psych Congress 2024 (GlobeNewswire)
Oct-19-24 07:30AM	3 Bargain Stocks to Buy in a Market That's Priced for Perfection (Motley Fool)
Oct-15-24 07:00AM	Axsome Therapeutics to Report Third Quarter 2024 Financial Results on November 12 (GlobeNewswire)
Sep-29-24 07:32AM	1 Under-the-Radar Biotech Stock to Buy and Hold (Motley Fool)
Sep-24-24 07:00AM	Axsome Therapeutics Presents Data from Multiple Programs at Sleep Europe 2024 (GlobeNewswire)
Sep-04-24 07:00AM	Axsome Therapeutics Announces FDA Acceptance of NDA Resubmission for AXS-07 for the Acute Treatment of Migraine (GlobeNewswire) +6.59%
Aug-27-24 07:00AM	Axsome Therapeutics to Participate in Investor Conferences in September (GlobeNewswire)
07:00AM	Loading…
Aug-21-24 07:00AM	Axsome Therapeutics Reaches Agreement to Dismiss Sunosi (Solriamfetol) Patent Litigation with Sandoz Inc. (GlobeNewswire)
Aug-16-24 05:43AM	Jim Cramer Thinks Axsome Therapeutics Inc (NASDAQ:AXSM) Stock Can Double (Insider Monkey)
Aug-05-24 01:45PM	Axsome Therapeutics (AXSM) Q2 2024 Earnings Call Transcript (Motley Fool)
12:15PM	Why Axsome Therapeutics Stock Is Sinking Today (Motley Fool)
11:30AM	Axsome (AXSM) Q2 Loss Widens Y/Y, Revenues Beat Estimates (Zacks)
07:00AM	Axsome Therapeutics Reports Second Quarter 2024 Financial Results and Provides Business Update (GlobeNewswire)
Jul-25-24 08:30AM	Global Fibromyalgia Treatment Market Projected To Reach $3.86 Billion By 2031 as Positive Growth Trends Expected (GlobeNewswire)
Jul-23-24 02:57PM	7 Biotech Stocks to Keep on Your Clinical Radar (InvestorPlace)
Jul-22-24 03:06PM	Axsome Therapeutics' CNS Portfolio Poised for Major Growth - Analyst Predicts Strong Future (Benzinga)
Jul-15-24 07:15AM	Bull Market and Beyond: 2 Stocks Just Waiting to Soar (Motley Fool)
Jul-11-24 07:00AM	Axsome Therapeutics to Report Second Quarter 2024 Financial Results on August 5 (GlobeNewswire)
Jul-05-24 02:14PM	The 3 Best Biotech Stocks to Buy in July 2024 (InvestorPlace)
Jul-04-24 10:01AM	3 Undervalued Biotech Gems With 200%+ Analyst Price Targets (InvestorPlace)
Jun-11-24 12:35PM	Why Axsome Therapeutics Stock Is Sinking Today (Motley Fool)
Jun-05-24 11:30AM	Axsome (AXSM) Down 6.1% Since Last Earnings Report: Can It Rebound? (Zacks)
07:35AM	Loading…
07:35AM	Axsome Therapeutics Settles Sunosi (solriamfetol) Patent Litigation with Unichem Laboratories (GlobeNewswire)
Jun-04-24 07:00AM	Axsome Therapeutics Joins the American Migraine Foundation to Highlight Unmet Treatment Needs During Migraine & Headache Awareness Month (GlobeNewswire)
Jun-03-24 07:00AM	Axsome Therapeutics Supports Alzheimer's & Brain Awareness Month (GlobeNewswire)
May-30-24 07:00AM	Axsome Therapeutics to Participate in Upcoming Investor Conferences (GlobeNewswire)
May-29-24 07:00AM	Axsome Therapeutics Highlights Data on Solriamfetol Demonstrating Improvement in Cognitive Function in Patients with Obstructive Sleep Apnea or Narcolepsy at SLEEP 2024 (GlobeNewswire)
May-28-24 07:00AM	Axsome Therapeutics Presents Data from Multiple Programs at the 2024 American Society of Clinical Psychopharmacology Annual (ASCP) Meeting (GlobeNewswire)
May-18-24 06:47AM	3 Monster Stocks in the Making You Can Buy Right Now (Motley Fool)
May-13-24 07:57PM	15 Most Depressed States in the US (Insider Monkey)
May-11-24 10:00AM	The 3 Most Undervalued Biotech Stocks to Buy in May 2024 (InvestorPlace)
09:00AM	Prediction: These 2 Growth Stocks Could Triple By 2030 (Motley Fool)
May-08-24 07:00AM	Axsome Therapeutics to Present at Upcoming Investor Conferences (GlobeNewswire)
May-07-24 11:26AM	Axsome (AXSM) Q1 Loss Widens Y/Y, Revenues Beat Estimates (Zacks)
11:17AM	Axsome Therapeutics, Inc. (NASDAQ:AXSM) Q1 2024 Earnings Call Transcript (Insider Monkey)
03:01AM	Axsome Therapeutics Inc (AXSM) (Q1 2024) Earnings Call Transcript Highlights: Soaring Revenues ... (GuruFocus.com)
May-06-24 10:55PM	Q1 2024 Axsome Therapeutics Inc Earnings Call (Thomson Reuters StreetEvents)
01:00PM	Axsome Therapeutics (AXSM) Q1 2024 Earnings Call Transcript (Motley Fool)
12:53PM	AXSM Stock Earnings: Axsome Therapeutics Beats EPS, Beats Revenue for Q1 2024 (InvestorPlace)
07:00AM	Axsome Therapeutics Reports First Quarter 2024 Financial Results and Provides Business Update (GlobeNewswire)
May-03-24 08:30AM	Should You Buy Axsome Therapeutics (AXSM) Ahead of Earnings? (Zacks)
May-01-24 07:00AM	Axsome Therapeutics Recognizes May as Mental Health Awareness Month (GlobeNewswire)
Apr-30-24 03:20PM	3 Biotech Stocks with Blockbuster Drug Pipelines: April Edition (InvestorPlace)
Apr-29-24 04:01PM	Ginkgo Bioworks Announces Nomination of Myrtle Potter and Ross Fubini to Board of Directors (PR Newswire)
10:00AM	Earnings Preview: Axsome Therapeutics (AXSM) Q1 Earnings Expected to Decline (Zacks)
Apr-22-24 09:16AM	15 Most Black States in the US (Insider Monkey)
Apr-15-24 07:00AM	Axsome Therapeutics Highlights Innovative Neuroscience Portfolio at the American Academy of Neurology (AAN) 2024 Annual Meeting (GlobeNewswire)
Apr-10-24 07:00AM	Axsome Therapeutics to Report First Quarter 2024 Financial Results on May 6 (GlobeNewswire)
Apr-02-24 10:24AM	Axsome (AXSM) Begins Solriamfetol Binge Eating Phase III Study (Zacks)
12:17AM	Insider Sell: COO Mark Jacobson Sells 24,662 Shares of Axsome Therapeutics Inc (AXSM) (GuruFocus.com)
Apr-01-24 07:00AM	Axsome Therapeutics Initiates ENGAGE Phase 3 Trial of Solriamfetol for the Treatment of Binge Eating Disorder (GlobeNewswire)
Mar-27-24 07:44AM	3 Strong Buy Biotech Stocks to Add to Your Q2 Must-Watch List (InvestorPlace)
Mar-26-24 11:24AM	Axsome's (AXSM) Narcolepsy Drug Study Meets Primary Goal (Zacks)
06:24AM	30 Countries with the Lowest Depression Rates (Insider Monkey)
04:56AM	20 Cloudiest Cities in the U.S., Ranked (Insider Monkey)
Mar-25-24 07:00AM	Axsome Therapeutics Announces Results of CRESCENDO Narcolepsy Patient Survey Demonstrating Unmet Needs in Treated Narcolepsy Type 1 Patients (GlobeNewswire)
06:30AM	Axsome Therapeutics Announces AXS-12 Achieves Primary Endpoint in the SYMPHONY Phase 3 Trial in Narcolepsy (GlobeNewswire)
Mar-23-24 06:45AM	Buying These Dirt-Cheap Stocks Could Be a Brilliant Move (Motley Fool)
Mar-22-24 10:00AM	Axsome Triumphs Over Major Depressive Disorder With Auvelity (GuruFocus.com)
Mar-21-24 11:30AM	Why Is Axsome (AXSM) Down 4% Since Last Earnings Report? (Zacks)
Mar-20-24 12:12PM	Axsome (AXSM) Begins Dosing in Depression Study on Sunosi (Zacks)
Mar-19-24 07:00AM	Axsome Therapeutics Initiates PARADIGM Phase 3 Trial of Solriamfetol for the Treatment of Major Depressive Disorder (GlobeNewswire) +5.97%
Mar-13-24 03:32PM	11 Oversold NASDAQ Stocks To Buy Right Now (Insider Monkey)
Mar-05-24 07:00AM	Axsome Therapeutics to Present at the Leerink Partners Global Biopharma Conference (GlobeNewswire)
Feb-27-24 07:00AM	Axsome Therapeutics to Present at the TD Cowen 44th Annual Healthcare Conference (GlobeNewswire)
Feb-26-24 03:04PM	3 Under-the-Radar Biotech Stocks With Upcoming Catalysts in 2024 (InvestorPlace)
08:50AM	3 Biotech Stocks to Buy and Hold for the Next 10 Years (Motley Fool)
Feb-21-24 10:39AM	Axsome (AXSM) Stock Falls Despite Q4 Earnings & Revenue Beat (Zacks)
09:23AM	Axsome Therapeutics, Inc. (NASDAQ:AXSM) Q4 2023 Earnings Call Transcript (Insider Monkey)
Feb-20-24 10:39PM	Q4 2023 Axsome Therapeutics Inc Earnings Call (Thomson Reuters StreetEvents) -12.57%
08:15AM	Axsome Therapeutics (AXSM) Reports Q4 Loss, Tops Revenue Estimates (Zacks)
07:31AM	Axsome Therapeutics Inc (AXSM) Reports Robust Revenue Growth in Q4 and Full Year 2023 (GuruFocus.com)
07:00AM	Axsome Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update (GlobeNewswire)
Feb-13-24 10:00AM	Axsome Therapeutics (AXSM) Expected to Beat Earnings Estimates: Can the Stock Move Higher? (Zacks) -5.51%
Feb-08-24 07:45AM	2 Stocks That Could Double Your Money in 5 Years (Motley Fool)
Jan-23-24 11:01AM	Axsome Therapeutics Stock Showing Leadership, Earns 91 RS Rating (Investor's Business Daily)
07:00AM	Axsome Therapeutics to Report Fourth Quarter and Full Year 2023 Financial Results on February 20 (GlobeNewswire)
Jan-05-24 10:21AM	Axsome (AXSM) Stock Rises on Stellar Q4 Preliminary Results (Zacks)
Jan-04-24 07:00AM	Axsome Therapeutics Provides Preliminary Fourth Quarter and Full Year 2023 Net Revenue and 2024 Anticipated Milestones (GlobeNewswire) +7.75%
Jan-03-24 05:20AM	3 Stocks That Have Turned $50,000 Into More Than $500,000 in Just 5 Years (Motley Fool)
Jan-02-24 08:45AM	2 Biotech Stocks You Can Buy and Hold for the Next Decade (Motley Fool)
Jan-01-24 06:50AM	Prediction: These 3 Stocks Will Soar in 2024 (Motley Fool)
Dec-11-23 07:00AM	Axsome Therapeutics Presents New Data and Post-Hoc Analyses of Auvelity in Patients with Major Depressive Disorder at the American College of Neuropsychopharmacology (ACNP) 2023 Annual Meeting (GlobeNewswire)
Dec-10-23 06:56AM	3 Unstoppable Stocks to Buy Right Now (Motley Fool)
Dec-07-23 07:00AM	Axsome Therapeutics Hosts Solriamfetol Virtual Investor Event with Expert Thought Leaders Today (GlobeNewswire)
Nov-28-23 06:51PM	Axsome Therapeutics, Inc. investors: Please contact the Portnoy Law Firm to recover your losses; December 7, 2023 deadline. (GlobeNewswire)
Nov-27-23 09:50AM	11 Best Upside Stocks To Buy Right Now (Insider Monkey) +5.93%
Nov-22-23 07:00AM	Axsome Therapeutics to Host Solriamfetol Virtual Investor Event on December 7 (GlobeNewswire)
05:30AM	3 Biotech Stocks That Could Be Millionaire Makers (Motley Fool)
Nov-21-23 07:00AM	Axsome Therapeutics to Present at the Piper Sandler 35th Annual Healthcare Conference (GlobeNewswire)
Nov-11-23 06:50AM	3 Growth Stocks to Buy Right Now Without Any Hesitation (Motley Fool)
Nov-09-23 10:23AM	3 Healthcare Stocks That Have More Than Doubled in Value Since the Fed Started Raising Interest Rates (Motley Fool)

Axsome Therapeutics, Inc. is a commercial-stage biopharmaceutical company, which engages in the development of novel therapies for the management of central nervous system disorders. Its portfolio consists of Products Overview and Pipeline Overview. The Products Overview includes Auvelity and Sunosi. The Pipeline Overview contain AXS-05, AXS-07, AXS-12, and AXS-14. The company was founded by Herriot Tabuteau on January 12, 2012 and is headquartered in New York, NY.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Coleman Mark	Director	Nov 19 '24	Option Exercise	5.94	33,410	198,455	48,010	Nov 20 04:30 PM
Saad Mark E	Director	Sep 11 '24	Option Exercise	3.67	11,016	40,429	21,018	Sep 11 07:00 PM
Saad Mark E	Director	Sep 11 '24	Sale	91.31	11,016	1,005,871	10,002	Sep 11 07:00 PM
Saad Mark E	Director	Sep 11 '24	Proposed Sale	91.31	11,016	1,005,843		Sep 11 04:32 PM
Jacobson Mark L.	Chief Operating Officer	Aug 09 '24	Option Exercise	4.04	47,739	192,866	53,522	Aug 09 07:27 PM
Jacobson Mark L.	Chief Operating Officer	Aug 09 '24	Sale	84.26	47,739	4,022,488	5,783	Aug 09 07:27 PM
Jacobson Mark L.	Officer	Aug 09 '24	Proposed Sale	84.26	47,739	4,022,490		Aug 09 05:07 PM
Jacobson Mark L.	Chief Operating Officer	May 29 '24	Option Exercise	1.30	13,693	17,801	13,693	May 29 08:12 PM
Jacobson Mark L.	Chief Operating Officer	May 29 '24	Sale	74.31	7,910	587,813	5,783	May 29 08:12 PM
Coleman Mark	Director	May 28 '24	Sale	75.21	5,249	394,775	19,848	May 29 08:11 PM
Coleman Mark	Director	May 29 '24	Sale	75.14	5,248	394,333	14,600	May 29 08:11 PM
Jacobson Mark L.	Chief Operating Officer	Apr 01 '24	Option Exercise	1.30	24,662	32,061	24,662	Apr 01 06:46 PM
Jacobson Mark L.	Chief Operating Officer	Apr 01 '24	Sale	77.24	24,662	1,904,942	0	Apr 01 06:46 PM
JEFFS ROGER	Director	Mar 14 '24	Option Exercise	24.01	29,976	719,787	137,732	Mar 15 08:05 PM
JEFFS ROGER	Director	Mar 15 '24	Option Exercise	29.91	2,347	70,199	123,103	Mar 15 08:05 PM
JEFFS ROGER	Director	Mar 14 '24	Sale	69.70	29,976	2,089,387	120,756	Mar 15 08:05 PM
JEFFS ROGER	Director	Mar 15 '24	Sale	71.61	2,347	168,062	120,756	Mar 15 08:05 PM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

AXSM

Axsome Therapeutics Inc

Upgrade your FINVIZ experience